Sera Prognostics

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

The study details the validation of the mass spec-based preterm birth test, which the company launched nationwide last month through its agreement with LabCorp.

The agreement will allow Sera to leverage LabCorp's sales force and networks, but similar deals have failed to deliver for proteomics firms in the past.

Sera plans to make the test for preterm birth available nationwide this year with LabCorp as the exclusive US distributor.

A health-economic model of the company's preterm birth test found it could lower infant mortality by 23 percent and yield annual savings of around $500 million.

According to one physician familiar with the test, it is a much needed diagnostic tool, but without insurance coverage it is too expensive for wide use.

Published this week in AJOG, the study found that the test could predict delivery before 37 weeks with 75 percent sensitivity and 74 percent specificity.

The mass spec-based proteomic test identified women who gave birth at or before 35 weeks gestation with an area under the receiver operating curve of .93.

This fall the company is rolling out a limited commercial launch of the MRM mass spectrometry-based proteomic test, with a broader launch to come next year.

With the additional funding, Sera aims to develop new tests for predicting the risk of preterm birth in women in developing countries, the company said.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.